Chemotherapeutics in the treatment of multiple sclerosis
The likely pathogenic mechanisms of multiple sclerosis (MS) provide a sound rationale for investigating the efficacy of drugs possessing immunosuppressive or immunomodulatory properties. With proven efficacy, safety and tolerability, interferon beta formulations and glatiramer acetate have become th...
Main Authors: | Bernd C. Kieseier, Douglas R. Jeffery |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-09-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285610379885 |
Similar Items
-
Defining a role for laquinimod in multiple sclerosis
by: Bernd C. Kieseier
Published: (2014-07-01) -
Atacicept: targeting B cells in multiple sclerosis
by: Hans-Peter Hartung, et al.
Published: (2010-07-01) -
Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
by: Martin Stangel, et al.
Published: (2015-01-01) -
Review: Innovative monoclonal antibody therapies in multiple sclerosis
by: Ralf A. Linker, et al.
Published: (2008-07-01) -
Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner
by: Celia Oreja-Guevara, et al.
Published: (2014-03-01)